Secondary Logo

Most Popular Articles

Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY

Potkin, Steven G.; Loze, Jean-Yves; Forray, Carlos; More

International Clinical Psychopharmacology. 32(3):147-154, May 2017.

Optimal treatment for obsessive compulsive disorder: a randomized controlled feasibility study of the clinical-effectiveness and cost-effectiveness of cognitive-behavioural therapy, selective serotonin reuptake inhibitors and their combination in the management of obsessive compulsive disorder

Fineberg, Naomi A.; Baldwin, David S.; Drummond, Lynne M.; More

International Clinical Psychopharmacology. 33(6):334-348, November 2018.

Methodological challenges in indirect treatment comparisons: spotlight on a recent comparison of long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia

Singh, Arun; Gopal, Srihari; Kim, Edward; More

International Clinical Psychopharmacology. 33(4):213-216, July 2018.

Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate

Montalvo, Itziar; Ortega, Laura; López, Xavi; More

International Clinical Psychopharmacology. 28(1):46-49, January 2013.

Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder

Boulenger, Jean-Philippe; Loft, Henrik; Olsen, Christina Kurre

International Clinical Psychopharmacology. 29(3):138-149, May 2014.

The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies

Weiss, Catherine; Weiller, Emmanuelle; Baker, Ross A.; More

International Clinical Psychopharmacology. 33(5):255-260, September 2018.

Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: a systematized review

Albert, Umberto; Carmassi, Claudia; Cosci, Fiammetta; More

International Clinical Psychopharmacology. 31(5):249-258, September 2016.

Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies

Earley, Willie; Durgam, Suresh; Lu, Kaifeng; More

International Clinical Psychopharmacology. 32(6):319-328, November 2017.

Results from a drug utilization study of extended release quetiapine fumarate prescribed by psychiatrists as treatment for major depressive disorder in selected countries in the European Union

Brody, Robert S.; Liss, Charles L.; Wray, Heather; More

International Clinical Psychopharmacology. 33(2):59-65, March 2018.

Increase in brain-derived neurotrophic factor in first episode psychotic patients after treatment with atypical antipsychotics

González-Pinto, Ana; Mosquera, Fernando; Palomino, Aitor; More

International Clinical Psychopharmacology. 25(4):241-245, July 2010.

A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia

Luthringer, Remy; Staner, Luc; Noel, Nadine; More

International Clinical Psychopharmacology. 22(5):299-308, September 2007.

Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics

Kwon, Jun Soo; Kim, Sung Nyun; Han, Jaewook; More

International Clinical Psychopharmacology. 30(6):320-328, November 2015.

Antidepressant combination versus antidepressants plus second-generation antipsychotic augmentation in treatment-resistant unipolar depression

Gobbi, Gabriella; Ghabrash, Maykel F.; Nuñez, Nicolas; More

International Clinical Psychopharmacology. 33(1):34-43, January 2018.

A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of venlafaxine extended release and a long-term extension study for patients with major depressive disorder in Japan

Higuchi, Teruhiko; Kamijima, Kunitoshi; Nakagome, Kazuyuki; More

International Clinical Psychopharmacology. 31(1):8-19, January 2016.

D-cycloserine does not enhance exposure–response prevention therapy in obsessive–compulsive disorder

Storch, Eric A.; Merlo, Lisa J.; Bengtson, Michael; More

International Clinical Psychopharmacology. 22(4):230-237, July 2007.

Show: